HDAC9 and cancer: Interestingly, belinostat, which is widely used in anti-cancer therapy as it induces apoptosis via the inhibition of histone deacetylases (HDAC), thus promoting excessive transcription in cells [28,29], led to a significant decrease in the expression of the region of interest.